22 Jul 2021
Spex Capital and MedCity Sign Exclusive New Partnership to Boost Investments in Promising Healthcare Technology Companies
Spex Capital, the digital health and medical technology investment firm, has partnered with MedCity to identify and fund promising health technology companies, accelerating their journey to commercialization and adoption in global health systems.
The exclusive partnership will support several calls for innovative companies seeking investment, with the first call being launched in September and focusing on companies seeking seed and Series A investments.
As the life sciences cluster organization for London, MedCity has well established relationships across the UK ecosystem and with international life science clusters. As part of the new partnership with Spex Capital, MedCity will use its extensive networks and expertise to attract applications from investor-ready companies that develop digital health technologies and cutting-edge medical technologies.
The investment firm will invest in the most viable of these companies, and with a fundraising target of £ 100million, Spex Capital will be truly implementing a change in digital healthcare. The most promising companies will be offered tickets between 500,000 and 5 million pounds.
Founded in 2021 by serial healthcare tech entrepreneur Claudio D’Angelo, London-based Spex Capital already has a portfolio of seven high-growth companies.
“There is an incredible pool of talent with unexpressed potential in digital health and medical technology, but many innovative companies in the sector do not have access to the right opportunities at their early stages due to a lack of funds and of experience. »Comments Claudio D’Angelo, founder and CEO of Spex Capital. “This is where Spex Capital comes in. Specializing in promoting disruptive businesses at an early stage, our goal is to achieve breakthroughs in healthcare systems globally. I am happy to be working again with MedCity on an exclusive basis with my new company. We’ve refined the process over the years to provide a more efficient review process and I’m excited to see what this call will pay off in terms of talent.
MedCity COO Nicki Bromwich sees the partnership as a natural alignment of shared interests: “Through its funding of transformative health technologies, Spex Capital is allied with MedCity’s own mission to drive innovation and drive investment in the life sciences sector to ultimately improve human health and patients. results. “
Spex Capital was launched earlier this year, with a strong team of fifteen people in place. Comprised of six members of the investment team, seven senior advisors and two venture capital partners, the team was carefully chosen based on the quality of their background and complementary skills in the industry.
Based in London and leveraging its global reach in the industry, Spex Capital is unique in the international proposition it offers to entrepreneurs and investors in healthcare technology. Prior to launch, the company had already established a world-class ecosystem through partnerships and relationships with accelerators and incubators, universities, hospitals, embassies, chambers of commerce, trade bodies, payers and systems. healthcare providers on all continents to source the highest quality technologies from around the world. .